Zachary Roberts Sells 27,199 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 27,199 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the sale, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. This represents a 5.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Allogene Therapeutics Trading Up 3.2 %

Shares of NASDAQ ALLO opened at $1.94 on Friday. The stock has a fifty day simple moving average of $2.12 and a 200-day simple moving average of $2.51. Allogene Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $5.78. The stock has a market capitalization of $406.76 million, a PE ratio of -1.24 and a beta of 0.86.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. Finally, Piper Sandler reduced their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Institutional Trading of Allogene Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. abrdn plc purchased a new position in shares of Allogene Therapeutics in the fourth quarter valued at approximately $776,000. Nordea Investment Management AB lifted its holdings in Allogene Therapeutics by 2.1% during the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock worth $986,000 after buying an additional 9,635 shares in the last quarter. Barclays PLC boosted its position in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after buying an additional 172,745 shares during the period. Geode Capital Management LLC grew its stake in shares of Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after acquiring an additional 407,070 shares in the last quarter. Finally, MML Investors Services LLC purchased a new stake in shares of Allogene Therapeutics during the third quarter worth $56,000. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).